Market Closed -
Sao Paulo
04:06:00 2024-04-30 pm EDT
|
5-day change
|
1st Jan Change
|
10.2
BRL
|
-0.58%
|
|
-1.07%
|
-1.92%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,571
|
2,148
|
1,313
|
1,756
|
2,545
|
1,228
|
Enterprise Value (EV)
1 |
2,072
|
2,897
|
2,130
|
2,700
|
3,659
|
2,319
|
P/E ratio
|
39.4
x
|
51.9
x
|
-13.4
x
|
-312
x
|
-11.2
x
|
-5.4
x
|
Yield
|
0.64%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.46
x
|
2
x
|
1.41
x
|
1.54
x
|
2.35
x
|
1.04
x
|
EV / Revenue
|
1.92
x
|
2.7
x
|
2.29
x
|
2.38
x
|
3.37
x
|
1.97
x
|
EV / EBITDA
|
10.5
x
|
14.6
x
|
44.5
x
|
17.7
x
|
150
x
|
32.4
x
|
EV / FCF
|
-160
x
|
50.6
x
|
45.1
x
|
142
x
|
306
x
|
-59.5
x
|
FCF Yield
|
-0.63%
|
1.98%
|
2.22%
|
0.7%
|
0.33%
|
-1.68%
|
Price to Book
|
1.25
x
|
1.68
x
|
1.1
x
|
1.5
x
|
2.68
x
|
1.34
x
|
Nbr of stocks (in thousands)
|
118,018
|
118,289
|
118,287
|
117,283
|
117,810
|
118,080
|
Reference price
2 |
13.31
|
18.16
|
11.10
|
14.97
|
21.60
|
10.40
|
Announcement Date
|
3/20/19
|
3/17/20
|
3/18/21
|
3/16/22
|
3/23/23
|
3/22/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,077
|
1,073
|
928.8
|
1,137
|
1,085
|
1,180
|
EBITDA
1 |
197.2
|
198.1
|
47.9
|
152.6
|
24.34
|
71.52
|
EBIT
1 |
122.4
|
125.4
|
-21.38
|
82.22
|
-43.12
|
32.74
|
Operating Margin
|
11.37%
|
11.69%
|
-2.3%
|
7.23%
|
-3.97%
|
2.78%
|
Earnings before Tax (EBT)
1 |
70.05
|
65.71
|
-73.07
|
2.456
|
-233.2
|
-199.5
|
Net income
1 |
40.09
|
41.3
|
-97.42
|
-5.625
|
-227.8
|
-227.9
|
Net margin
|
3.72%
|
3.85%
|
-10.49%
|
-0.49%
|
-21%
|
-19.32%
|
EPS
2 |
0.3380
|
0.3499
|
-0.8253
|
-0.0480
|
-1.934
|
-1.926
|
Free Cash Flow
1 |
-12.96
|
57.25
|
47.19
|
18.96
|
11.98
|
-38.98
|
FCF margin
|
-1.2%
|
5.34%
|
5.08%
|
1.67%
|
1.1%
|
-3.3%
|
FCF Conversion (EBITDA)
|
-
|
28.9%
|
98.52%
|
12.43%
|
49.22%
|
-
|
FCF Conversion (Net income)
|
-
|
138.62%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0845
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/20/19
|
3/17/20
|
3/18/21
|
3/16/22
|
3/23/23
|
3/22/24
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
298.5
|
269.7
|
275.2
|
266.5
|
280.8
|
EBITDA
1 |
77.3
|
32
|
47.2
|
59.2
|
46.6
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/11/21
|
3/16/22
|
5/16/22
|
8/15/22
|
11/11/22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
501
|
749
|
817
|
944
|
1,115
|
1,091
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.541
x
|
3.78
x
|
17.05
x
|
6.187
x
|
45.81
x
|
15.25
x
|
Free Cash Flow
1 |
-13
|
57.3
|
47.2
|
19
|
12
|
-39
|
ROE (net income / shareholders' equity)
|
4.01%
|
3.82%
|
-7.27%
|
0.16%
|
-20%
|
-22.7%
|
ROA (Net income/ Total Assets)
|
3.4%
|
3.4%
|
-0.54%
|
2.02%
|
-1.04%
|
0.77%
|
Assets
1 |
1,178
|
1,215
|
18,010
|
-278.2
|
21,802
|
-29,426
|
Book Value Per Share
2 |
10.70
|
10.80
|
10.10
|
9.990
|
8.060
|
7.770
|
Cash Flow per Share
2 |
0.6200
|
0.7500
|
1.940
|
1.080
|
1.860
|
1.850
|
Capex
1 |
86
|
75.3
|
66.7
|
100
|
113
|
91.5
|
Capex / Sales
|
7.99%
|
7.02%
|
7.18%
|
8.84%
|
10.42%
|
7.76%
|
Announcement Date
|
3/20/19
|
3/17/20
|
3/18/21
|
3/16/22
|
3/23/23
|
3/22/24
|
|
1st Jan change
|
Capi.
|
---|
| -1.92% | 233M | | -19.14% | 8.22B | | +45.10% | 3.73B | | -8.23% | 2.46B | | -38.71% | 2.46B | | -8.84% | 2.36B | | -13.72% | 1.78B | | -19.73% | 1.52B | | -40.78% | 1.21B | | +8.32% | 1.12B |
Medical & Diagnostic Laboratories
|